Novo Nordisk has appointed Omnicom as agency of record for its U.S. media planning and buying, a spokesperson confirmed. COMvergence values the U.S. account at $520 million and the global account at $618 million. The appointment signals a major consumer marketing push behind the GLP-1 medications…
The account is the paid-media engine behind the company's two GLP-1 medications, Ozempic and Wegovy. Novo Nordisk manufactures both, and both are formulations of the same peptide, semaglutide. Omnicom will decide where the advertising appears, negotiate rates with television networks, digital platforms, and publishers, and place campaigns across channels. A U.S. valuation of $520 million places the company among the largest pharmaceutical advertisers in the country, a position built on products whose demand is unusually sensitive to consumer awareness.
For peptide science, the assignment matters for a reason unrelated to pharmacology. Consumer advertising does not change a molecule's behavior, but it changes who arrives in a clinic asking for treatment by name, how quickly they start therapy, and how long they stay on it. Those are the same variables that shape real-world evidence, prescribing patterns, and manufacturing capacity requirements. A media decision of this size is a scientific variable in its own right, and its effects will be readable in clinical data for years.
Media planning and buying covers the strategy for where advertising appears, the negotiation of rates, and the placement of campaigns across channels. Agency of record status means Omnicom holds that mandate on an ongoing basis rather than competing for the business project by project, the standard industry structure for clients that buy media at this scale. The COMvergence figures concentrate the company's measured billings heavily in the United States, consistent with a market where direct-to-consumer advertising for prescription medicines is legal and routine.
A Novo Nordisk spokesperson said the company intends to work with Omnicom on consumer-focused strategies and emerging channels and technologies to raise awareness of its medicines for chronic conditions such as obesity and diabetes. The spokesperson said: "We look forward to working with the Omnicom team as we continue to scale consumer-focused strategies and connect with patients through emerging channels and technologies..."
The phrase "emerging channels and technologies" points beyond conventional television and print toward connected television, social platforms, search, and digital health media, where patients increasingly encounter treatment options. For a franchise built on chronic, long-duration therapy, sustained consumer reach is a commercial requirement. A patient who starts a GLP-1 receptor agonist may remain on therapy for years, and persistence depends on the drug staying on that patient's and that prescriber's radar. Awareness is not a one-time event for a chronic therapy; it must be renewed continuously, because discontinuation is the central commercial risk in metabolic disease and because new patients enter the treatment-eligible population every year.
Consumer strategy in this category therefore extends past the first prescription. Refill reminders, injection training, and realistic expectations about gastrointestinal side effects are part of keeping a patient on an injectable therapy, so the same account that drives new starts also carries the retention function.
The mandate sits inside Omnicom's media division. Omnicom Media Group operates agencies including OMD, PHD, and Hearts & Science, and which operating agency will staff the Novo Nordisk business has not been disclosed. Compensation for accounts of this scale has shifted over the past decade from media commissions to negotiated fees, a change accelerated by the Association of National Advertisers' 2016 study of non-transparent practices in digital media buying, which led many large advertisers to demand audit rights and rebates. The fee structure matters on a $520 million assignment because it changes the agency's incentive: the fee is tied to the scope of work, not to the volume of media purchased.
The account will also cover two legally distinct forms of consumer drug advertising. Fully branded ads for Ozempic and Wegovy must satisfy FDA risk-disclosure requirements. Unbranded disease-awareness advertising, which describes a condition and urges a conversation with a doctor without naming a product, sits outside the prescription drug advertising rules and has become a major format in the obesity category. The company's "consumer-focused strategies" language covers both, and the two forms differ in what can be measured. Branded placements can be tracked to prescriptions by brand; unbranded placements can be credited only to the category, which makes their contribution to prescribing far harder to quantify.
The sharpest detail in the COMvergence numbers is the concentration. At $520 million, the U.S. portion is roughly 84 percent of the $618 million global valuation. That is not an artifact of revenue reporting; it is a consequence of law. The United States and New Zealand are the only two countries that permit direct-to-consumer advertising of prescription medicines. Elsewhere, branded consumer promotion is banned or heavily restricted, and pharmaceutical marketing shifts to physicians, payers, and unbranded disease-awareness campaigns. A Danish company's media account is overwhelmingly American because the American market is where consumer reach is purchasable at all.
That legal position has a specific constitutional foundation. Commercial speech receives First Amendment protection, and the FDA's authority over drug advertising rests on disclosure requirements rather than on prohibition of truthful promotion. The agency opened the door to DTC print advertising in 1985 and, with a 1997 guidance, established the broadcast framework that allowed television and radio ads under two conditions: a major statement of the principal risks, and adequate provision of the full prescribing information. Those two obligations still define the format of every branded drug advertisement in the United States.
FDA regulations also require that risk information be presented with a prominence reasonably comparable to the benefit claims, the requirement known as fair balance . Broadcast ads must carry a major statement of the most important risks, and advertisers must make the full prescribing information adequately available through a concurrent print ad, a website, or a toll-free number. In 2023 the FDA finalized a rule requiring that the major statement in television and radio ads be presented in a clear, conspicuous, and neutral manner, including on-screen text; the rule took effect in November 2024. The same risk-disclosure obligations apply in digital media, where character limits and interactive formats make compliance harder. Every placement must clear medical, legal, and regulatory review before it runs, which forces the media plan to accommodate clearance timelines that consumer packaged goods advertising never faces. An agency buying $520 million in U.S. media is therefore buying inventory that is unusually expensive to produce and to police.
This makes the account a bet on the durability of the U.S. regulatory posture. The framework is stable but not static. Congress has periodically considered restricting or banning direct-to-consumer drug advertising, and the FDA has shown it will intervene in individual campaigns. Any tightening of the rules would compress the value of the account; any expansion of permitted channels would enlarge it. For researchers, that linkage is the reason a media story belongs in the same file as a clinical readout: the regulatory environment that permits these ads is itself a variable in how quickly new metabolic therapies reach patients.
Ozempic and Wegovy are both semaglutide , a synthetic analog of glucagon-like peptide-1 GLP-1 , the incretin hormone secreted by intestinal L cells after food intake. The incretin effect, demonstrated experimentally in the 1960s, is the reason oral glucose provokes a larger insulin response than intravenous glucose at the same blood glucose level. GLP-1 is one of the system's two principal hormones; the other is glucose-dependent insulinotropic polypeptide. GLP-1 binds receptors on pancreatic beta cells and amplifies insulin secretion, but only when blood glucose is elevated, which is why the class carries a low risk of hypoglycemia relative to older insulin secretagogues.
The hormone also suppresses glucagon release from pancreatic alpha cells, slows gastric emptying, and acts on appetite centers in the central nervous system to reduce food intake and increase satiety. GLP-1 receptors are distributed across the pancreas, the gastrointestinal tract, and brain regions including the hypothalamus and brainstem, which is how one peptide can blunt glucagon, slow digestion, and reduce appetite at the same time. With chronic dosing, the gastrointestinal effects wane, and sustained weight loss on this class is attributed mainly to the central suppression of appetite rather than to the stomach. Those combined actions address both sides of the metabolic problem: glucose control and energy balance. That is why the same molecule supports one product aimed at type 2 diabetes and another aimed at weight management.
The molecule's engineering is the peptide chemistry that makes the franchise possible. Native GLP-1 is cleaved within minutes by the enzyme dipeptidyl peptidase-4 , so therapeutic use required a resistant analog. The first approved GLP-1 receptor agonist, exenatide, was discovered in the saliva of the Gila monster; its resistance came from a foreign sequence, not from chemical modification. Semaglutide is a different solution: a human-sequence analog in which the residue at position 8, the site of DPP-4 attack, is replaced by the non-natural amino acid 2-aminoisobutyric acid, a substitution from lysine to arginine at position 34 limits the available acylation sites, and an 18-carbon fatty diacid attached through a hydrophilic spacer to a lysine side chain binds albumin in circulation. Albumin binding slows clearance and extends the peptide's half-life to about one week, which is what permits once-weekly subcutaneous dosing with an injection device.
The evidence base has moved beyond glucose and body weight. The SUSTAIN program established the efficacy and cardiovascular profile of once-weekly semaglutide in type 2 diabetes; the STEP program quantified weight loss in people with obesity. The SELECT trial, a cardiovascular outcomes study in people with overweight or obesity and established cardiovascular disease who did not have diabetes, showed a reduction in major adverse cardiovascular events, and the FDA added that cardiovascular indication to Wegovy's label in 2024. Marketing at this scale shapes who enters that evidence pool, and the pool in turn shapes the real-world data that clinicians and payers rely on.
Because these are peptide drugs, their commercial scale is tied to manufacturing biology as much as to marketing. The science of the molecule and the science of production run in parallel, and the media investment is a claim about both.
Within those FDA constraints, a campaign on this scale has predictable effects on practice. The health services literature has consistently found that exposure to a branded campaign raises the probability that a patient will ask for the drug by name and that prescribers frequently accommodate such requests. Survey research conducted for the FDA and by the Kaiser Family Foundation has repeatedly found that physicians believe DTC advertising drives patients to request specific products and that a substantial share of physicians report writing the requested prescription. Patients arrive having encountered the brand name, and they ask for the product specifically.
For primary care clinicians and obesity medicine…
Peptides referenced: Semaglutide, Exenatide, Glucagon, GLP-1.
Related reading: The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings, Is Novo Nordisk Set for a 2026 Recovery Amid Competition and AI?, HOMETOWN HEALTH: GLP-1 drug “Tirzepatide” linked to lower heart attack risk in high-risk patients, MACE Risk May Be Reduced with GLP-1 Drug in High-Risk Patients.